Research on the treatment for the cure of Alpha 1 Deficiency continues to advance
The second phase of treatment is already underway Arrowhead ARO-AAT Phase 2 interim results in patients with alpha-1 liver disease demonstrate improvements in key parameters after six months of treatment. PASADENA, California Arrowhead Pharmaceuticals Inc. announced this September 2020 interim positive 24-week liver biopsy results in four subjects from AROAAT2002. An open-label phase 2 clinical […]
Research on the treatment for the cure of Alpha 1 Deficiency continues to advance Read More »







